Nuclera has expanded its Series C funding round to USD $87 million following a new USD $12 million extension led by Elevage ...

Cellistic has unveiled three new GMP manufacturing platforms designed to advance iPSC-derived cell therapies across ...

Oxford Drug Design has announced new in vivo results that further validate its emerging first‑in‑class oncology programme, ...

Fabentech has received Marketing Authorisation in France for Ricimed, an antidote designed to treat ricin poisoning, marking ...

The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...

HUTCHMED has advanced its ongoing study of surufatinib and camrelizumab for treatment‑naïve metastatic pancreatic ductal ...

Zenas BioPharma has announced positive findings from its phase 3 INDIGO trial evaluating obexelimab in patients with ...

Bial has introduced a new sublingual formulation of apomorphine in the UK, offering a fresh treatment option for adults with Parkinson’s disease who experience intermittent OFF episodes that are not ...

STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.

The inaugural Excellence in Healthcare Partnerships (EHP) Awards and Networking Evening is taking place at the Grand Connaught Rooms, London at 5pm on 5th February 2026. An evening of discussion, ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency for an extension of ...